Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Sep 6, 2015; 4(4): 468-479
Published online Sep 6, 2015. doi: 10.5527/wjn.v4.i4.468
Current management of autosomal dominant polycystic kidney disease
Jacob A Akoh
Jacob A Akoh, South West Transplant Centre, Plymouth Hospitals NHS Trust, Derriford Hospital, Plymouth PL6 8DH, United Kingdom
Author contributions: Akoh JA solely contributed to this paper.
Conflict-of-interest statement: The author has no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jacob A Akoh, FRCSEd, FRCS (Gen), Consultant General and Transplant Surgeon, South West Transplant Centre, Plymouth Hospitals NHS Trust, Derriford Hospital, Level 04, Plymouth PL6 8DH, United Kingdom. jacob.akoh@nhs.net
Telephone: : +44-1752-432650 Fax: +44-1752-517576
Received: June 1, 2015
Peer-review started: June 2, 2015
First decision: June 18, 2015
Revised: August 17, 2015
Accepted: August 30, 2015
Article in press: August 31, 2015
Published online: September 6, 2015
Core Tip

Core tip: Autosomal dominant polycystic kidney disease (ADPKD), the most frequent cause of genetic kidney disease affecting approximately 4 to 7 million individuals worldwide (7%-15% of patients on renal replacement therapy), is a systemic disorder mainly involving the kidney but cysts can also occur in other organs such as the liver, pancreas and arachnoid membrane. This paper discusses radiological evaluation of ADPKD, necessity for screening for intracranial aneurysms and current treatment strategies include reducing: cyclic adenosine monophosphate levels, cell proliferation and fluid secretion. It further discusses the role of surgery in managing ADPKD patients and highlights areas of new research.